

Zydus Cadila's total income from operations up by 15% in Q4

Ahmedabad, May 29, 2019

Announcing the results for the fourth quarter ended 31st March 2019, Zydus Cadila informed that it has registered total income from operations of Rs. 3,733 crores, up by 15% from Rs. 3,238 crores registered in the corresponding period last year on a consolidated basis. The Net Profit for the same period stood at Rs. 460 crores. The consolidated financial results include the results of operations of the acquired business of Heinz India Pvt. Ltd., for two months.

For the year ended 31st March 2019, on a consolidated basis, the company registered a Net Profit of Rs. 1,849 crores and the total income from operations stood at Rs. 13,166 crores, up by 10%.

Strengthening its regulatory pipeline, the company filed 29 ANDAs during the year with the US FDA, taking the cumulative filings to 360. The company received 74 ANDA approvals taking the total to 254 product approvals.

Furthering its research initiatives, during the year, the company entered into a collaborative research agreement with the Council of Scientific and Industrial Research (CSIR) - Institute of Microbial Technology (IMTECH) to identify new drug candidates for the treatment of drug-resistant infections. The company also made progress with its key research molecules, Desidustat, the Investigational New Drug targetted at treating anemia in Chronic Kidney Disease (CKD) patients and Saroglitazar for the treatment of Non-Alcoholic SteatoHepatitis (NASH).

During the year, the company also acquired 51% stake in Dehradun-based Windlas Healthcare Private Limited (WHPL).
